AstraZeneca Plc says it has begun enrolling adults for a US-funded, 30,000-subject late-stage study of its high profile Covid-19 vaccine candidate.
Trial participants will receive either two doses of the experimental vaccine, dubbed AZD1222, four weeks apart, or a placebo, the company said.
The trial is being conducted under US government’s Operation Warp Speed program, which aims to accelerate development, manufacturing and distribution of vaccines and treatments for Covid-19.
AZD1222 is already undergoing late-stage clinical trials in Britain, Brazil and South Africa, with additional trials planned in Japan and Russia. The trials, together with the US Phase III study, aim to enrol up to 50,000 participants globally.